Marginal structural models: application Daniel SPER Anaheim June 22 2009.

Slides:



Advertisements
Similar presentations
If we use a logistic model, we do not have the problem of suggesting risks greater than 1 or less than 0 for some values of X: E[1{outcome = 1} ] = exp(a+bX)/
Advertisements

Controlling for Time Dependent Confounding Using Marginal Structural Models in the Case of a Continuous Treatment O Wang 1, T McMullan 2 1 Amgen, Thousand.
M2 Medical Epidemiology
Introduction to Survival Analysis October 19, 2004 Brian F. Gage, MD, MSc with thanks to Bing Ho, MD, MPH Division of General Medical Sciences.
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
Informative Censoring Addressing Bias in Effect Estimates Due to Study Drop-out Mark van der Laan and Maya Petersen Division of Biostatistics, University.
Chance, bias and confounding
Causal Diagrams: Directed Acyclic Graphs to Understand, Identify, and Control for Confounding Maya Petersen PH 250B: 11/03/04.
Extension Article by Dr Tim Kenny
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
FINAL REVIEW BIOST/EPI 536 December 14, Outline Before the midterm: Interpretation of model parameters (Cohort vs case-control studies) Hypothesis.
Intermediate methods in observational epidemiology 2008 Instructor: Moyses Szklo Measures of Disease Frequency.
 Confounders are usually controlled with the “standard” response regression model.  The standard model includes confounders as covariates in the response.
Main Points to be Covered Cumulative incidence using life table method Difference between cumulative incidence based on proportion of persons at risk and.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
BIOST 536 Lecture 4 1 Lecture 4 – Logistic regression: estimation and confounding Linear model.
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Are exposures associated with disease?
Study Design and Analysis in Epidemiology: Where does modeling fit? Meaningful Modeling of Epidemiologic Data, 2010 AIMS, Muizenberg, South Africa Steve.
Introduction to Survival Analysis August 3 and 5, 2004.
Concepts of Interaction Matthew Fox Advanced Epi.
Evidence-Based Medicine 4 More Knowledge and Skills for Critical Reading Karen E. Schetzina, MD, MPH.
Simple Linear Regression
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
The Effect of Gender Based Violence (GBV) on Mortality: a longitudinal study of US women with & at risk for HIV Kathleen M. Weber Steve R. Cole, Jane Burke-Miller,
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
Excepted from HSRP 734: Advanced Statistical Methods June 5, 2008.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
1 1 Using Marginal Structural Model to Estimate and Adjust for Causal Effect of Post- discontinuation Chemotherapy on Survival in Cancer Trials Y. Wang,
HSRP 734: Advanced Statistical Methods July 31, 2008.
Community-based Adherence Clubs improve outcomes for stable ART patients: Outcomes from Cape Town, South Africa Anna Grimsrud 1, Maia Lesosky 1,2, Cathy.
CREATE Biostatistics Core THRio Statistical Considerations Analysis Plan.
Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Statistical Issues in the Analysis of Patient Outcomes April 11, 2003 Elizabeth Garrett Oncology Biostatistics Acknowledgement: Thanks to Ron Brookmeyer.
Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.
Lecture 12: Cox Proportional Hazards Model
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
A short introduction to epidemiology Chapter 9: Data analysis Neil Pearce Centre for Public Health Research Massey University Wellington, New Zealand.
Lecture 5: The Natural History of Disease: Ways to Express Prognosis
01/20151 EPI 5344: Survival Analysis in Epidemiology Cox regression: Introduction March 17, 2015 Dr. N. Birkett, School of Epidemiology, Public Health.
Satistics 2621 Statistics 262: Intermediate Biostatistics Jonathan Taylor and Kristin Cobb April 20, 2004: Introduction to Survival Analysis.
Instructor Resource Chapter 15 Copyright © Scott B. Patten, Permission granted for classroom use with Epidemiology for Canadian Students: Principles,
01/20151 EPI 5344: Survival Analysis in Epidemiology Confounding and Effect Modification March 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
POPLHLTH 304 Regression (modelling) in Epidemiology Simon Thornley (Slides adapted from Assoc. Prof. Roger Marshall)
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
Case-Control Studies September 2014 Alexander M. Walker MD, DrPH With Sonia Hernández-Díaz MD, DrPH.
1 Part09: Applications of Multi- level Models to Spatial Epidemiology Francesca Dominici & Scott L Zeger.
1 “The Effects of Sociodemographic Factors on the Hazard of Dying Among Aged Chinese Males and Females” Dudley L. Poston, Jr. and Hosik Min Department.
The parametric g-formula and inverse probability weighting
1 Study Design Imre Janszky Faculty of Medicine, ISM NTNU.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
1 Borgan and Henderson: Event History Methodology Lancaster, September 2006 Session 8.1: Cohort sampling for the Cox model.
Measures of disease frequency Simon Thornley. Measures of Effect and Disease Frequency Aims – To define and describe the uses of common epidemiological.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
Survival time treatment effects
Constructing Inverse Probability Weights for Dynamic Interventions
Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,
Harvard T.H. Chan School of Public Health
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Presenter: Wen-Ching Lan Date: 2018/03/28
Where did we stop? The Bayes decision rule guarantees an optimal classification… … But it requires the knowledge of P(ci|x) (or p(x|ci) and P(ci)) We.
EPID 799C, Lecture 22 Wednesday, Nov. 14, 2018
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Counterfactual models Time dependent confounding
Biomarkers as Endpoints
Presentation transcript:

Marginal structural models: application Daniel SPER Anaheim June

Application of MSM: a brief introduction Our goal –To estimate the average causal effect of highly active antiretroviral therapy on time to the combined outcome of death or AIDS. First, the results. AnalysisHR (95% CL) Crude0.97 (0.76, 1.24) Adjusted (baseline)0.66 (0.50, 0.86) Adjusted (time-updated)0.81 (0.61, 1.06) Weighted (baseline-stratified)0.52 (0.35, 0.76)

The data 1498 individuals –506 men, from the Multicenter AIDS Cohort Study –992 women, from Women’s Interagency HIV Study Entered study between 1995 and 2000 At baseline, participants typically: –between 31 and 46 years old –not receiving any antiretroviral therapy –CD4 count >350 cells/mm3 (80%+ over 200) –HIV RNA viral load > copies/ml

Simplified causal model for these data CD4 count 0 HAART 1 AIDS/death 2 CD4 count 2 HAART 3 AIDS/death 4 …but this diagram is incomplete.

Simplified causal model for these data CD4 count 0 HAART 1 AIDS/death 2 CD4 count 2 HAART 3 AIDS/death 4 This additional arrow is the key problem.

Simplified causal model for these data CD4 count 0 HAART 1 AIDS/death 2 CD4 count 2 HAART 3 AIDS/death 4 Controlling for CD4 count…

Simplified causal model for these data CD4 count 0 HAART 1 AIDS/death 2 CD4 count 2 HAART 3 AIDS/death 4 …blocks these paths…

Simplified causal model for these data CD4 count 0 HAART 1 AIDS/death 2 CD4 count 2 HAART 3 AIDS/death 4 …which means that we cannot assess this causal pathway.

Analysis: statistical models Overall decision: Cox proportional hazards models Several contrasting models for illustration –Crude model –Adjusted model (baseline covariates only) –Adjusted model (time-updated covariates) –Weighted (marginal structural) model

Model specification: crude Crude Cox proportional hazards model Hazard is modeled as a product of –an unspecified baseline hazard AND –beta times the time-updated exposure What we want from this model (and from all following models) is

Model specification: baseline-adjusted Baseline-stratified Cox proportional hazards model Hazard is modeled as a product of –an unspecified baseline hazard AND –the sum of beta times the time-updated exposure AND the vector of beta coefficients X baseline covariates Z

Model specification: time-updated adjusted Fully-stratified Cox proportional hazards model Hazard is modeled as a product of –an unspecified baseline hazard AND –the sum of beta times the time-updated exposure AND the vector of beta coefficients X time-updated covariates L

Model specification: marginal structural Marginal structural Cox proportional hazards model, baseline stratified. Under the assumptions of no uncontrolled confounding or selection bias, adequate positivity, consistency, and correct model specification, we estimate this model as: …weighted by inverse probability of treatment and censoring weights Wit. If the above assumptions are met, then

Analysis of marginal structural model To accommodate time-varying IPTC weights, we approximate the above model using a pooled logistic regression (a discrete time hazards model). When risk per unit time is small (i.e., less than 10%), then So, with (a) low risk per time unit, and (b) assumptions met, Thus, we can estimate the quantity of interest from the MSM: the causal log hazard ratio.

Technical note Some of you have noticed that this model includes baseline covariates L i0 As a result, we are not estimating a purely marginal model, but instead a baseline-stratified marginal structural Cox model. This is because we plan on stabilizing the IPTC weights – by including baseline covariates in numerators – to reduce variance of the final estimator. As a result we must include covariates in the final model to ensure complete control of confounding. We could leave the weights unstabilized, and get a purely marginal estimate.

Estimation of the weights: theory These weights are where Denominator is: –probability of current treatment X given history of treatment, covariate history, and contingent on being uncensored. Numerator is: –similar, but contingent on baseline covariates, not all covariate history. Note that the π in front means that we’re estimating cumulative probabilities: cumulative through time. The censoring weights are modeled analogously.

Estimation of the weights: practice Used logistic regression models to estimate time-varying weights for –confounding of treatment AND –right-censoring by drop-out (that is, non-administrative censoring) We made a simplifying intent-to-treat assumption: once exposed, always exposed. –This assumption correctly classifies 94% of person-time in these data, so seems warranted. –As a result of this assumption, “exposure history” is simply “how long have you been unexposed?” which is the same as “how long have you been on study?”

Estimation of the weights: specifics We created weights using the following variables: –age (modeled as four-knot cubic spline) –race –sex –CD4 count (baseline and updated) –viral RNA (baseline and updated) –use of non-HAART ART –calendar date of study enrollment (modeled as four- knot cubic spline) –use of cotrimoxazole prophylaxis –presence of HIV symptoms reported persistent fever, diarrhea, night sweats, or weight loss Weights calculated in this way, with these variables, showed adequate positivity.

Results (for real this time) AnalysisHR (95% CL) Crude0.97 (0.76, 1.24) Adjusted (baseline)0.66 (0.50, 0.86) Adjusted (time-updated)0.81 (0.61, 1.06) Weighted (baseline-stratified)0.52 (0.35, 0.76)

Results: visual representation When we apply weights to the observed population, we create a pseudopopulation in which there is no confounding of the exposure- outcome relationship (in theory). –Equivalent to standardization under some, limited circumstances Visual contrasts between exposed and unexposed – for example, an extended Kaplan- Meier type cumulative incidence curve – drawn in the pseudopopulation will provide a theoretically unbiased causal contrast

Extended Kaplan-Meier curves

Discussion and limitations Of course, we can never know for sure whether we have controlled for all confounding or selection bias. –Sensitivity analysis can help. When we stabilize on baseline covariates, we estimate a baseline conditional association rather than a marginal association. Is that a problem? –We can explore this by not stabilizing on baseline covariates AnalysisHR (95% CL) Weighted (baseline-stratified)0.52 (0.35, 0.76) Weighted (purely marginal)0.59 (0.38, 0.92)

Next step: the role of time scale (teaser) Our marginal structural Cox model used time- on-study as the time scale for analysis. But most randomized trials of a drug treatment like antiretroviral therapy think about time since initiation of treatment (time-on-treatment) as the time scale. It is easy to adapt marginal structural models to a new time scale: when we do, risk sets for relative hazards estimation will change. Does this affect our analysis? (Yes. Come see my talk Wednesday.)

MSM: marginal structural (SER) meeting My talk (Timescale): Wed am, Session DEALING IN ABSOLUTES Steve Cole’s talk (Measurement error correction in MSM): Wed. 3.30pm, Session MEASUREMENT BIAS Other relevant talks –Lauren Cain –Claire Margerison –Anjum Hajat –Chanelle Howe Posters –Robert Platt –Daniel Westreich –And probably half a dozen more that I’ve missed.

Acknowledgements MACS and WIHS Daniel Westreich is funded by NIH/NIAID 5 T32 AI Training in Sexually Transmitted Diseases and AIDS Stephen R. Cole is supported by NIH/NIAID R03-AI ; R01-AA-01759; P30-AI-50410

Marginal structural models: application Daniel SPER Anaheim June Thank you.